Foghorn Therapeutics Inc.
NASDAQ:FHTX
Overview | Financials
Company Name | Foghorn Therapeutics Inc. |
Symbol | FHTX |
Currency | USD |
Price | 8.86 |
Market Cap | 492,554,866 |
Dividend Yield | 0% |
52-week-range | 2.7 - 10.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Adrian H. B. Gottschalk |
Website | https://foghorntx.com |
An error occurred while fetching data.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD